Anti-CD22 (Epratuzumab)-CL2A-SN-38 ADC

  • Check with publisher
  • Published date: November 13, 2017
    • Shirley, New York, United States

This ADC product is comprised of an a Epratuzumab conjugated via a CL2A linker to a SN-38.The SN-38 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis.The SN-38 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, SN-38 binds to DNA, causes DNA damage. Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
SN38 (7-ethyl-10-hydroxy camptothecin) is an active metabolite of the cancer prodrug, irinotecan, with the ability of inhibiting Topoisomerase I, which is belong to the camptothecin family. SN-38 is formed via hydrolysis of irinotecan by carboxylesterases and metabolized via glucuronidation by UGT1A1

Result 0 votes
Bella
0 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • Anti-CD22 (clone 10F4)-AcBut-Calicheamicin ADC

    Anti-CD22 (clone 10F4)-AcBut-Calicheamicin ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of an anti-CD22 monoclonal antibody (clone 10F4) conjugated via a AcBut linker to a Calicheamicin. The Calicheamicin is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediat...

  • Anti-CD22 (clone RFB4)-MCC-DM1 ADC

    Anti-CD22 (clone RFB4)-MCC-DM1 ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of an anti-CD22 monoclonal antibody (clone RFB4) conjugated via a MCC linker to a DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within...

  • Anti-CD22 (10F4v3)-Mc-MMAF ADC

    Anti-CD22 (10F4v3)-Mc-MMAF ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of an anti-CD22 monoclonal antibody (clone 10F4v3) conjugated via a Mc linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Withi...